Thursday, August 17

Thursday, August 17

2 – 3:15 pm

Opening Keynote: Secrets Everyone in Health Care Needs to Know (101)

1CH  Join us for a humorous look at the realities of healthcare. In this session, we will unravel the secrets to working in today’s crazy healthcare environment. We will take a creative look at change, collaboration, and accountability. We will explore our legacy and why we are the way we are today. Come discover the secrets to excellent care, and learn how to put the energy back into ourselves and our team members.

3:30 – 4:30 pm

It's All GREEK To Me! The NEPENTHE Trial for Relapsed/Refractory Neuroblastoma; Personalized Molecularly Targeted Treatment (200)

1CH  Nearly 50% of patients with high-risk neuroblastoma suffer a relapse of their disease despite intensive upfront treatment. Unfortunately, relapsed high-risk neuroblastoma remains incurable in the large majority of patients. We have initiated a phase 1/1b investigational trial for patients with relapsed/refractory neuroblastoma, which provides patients with treatment that matches the genetic profile of their tumor. The NEPENTHE trial; NExt generation PErsonalized Neuroblastoma THErapy. In part one of this trial, a patient's tumor is sent for next generation sequencing-based cancer genomic profiling (NGS). Patients who have mutations in the anaplastic lymphoma kinase oncogene (ALK), RAS/MAPK pathway or who have TP53 wild-type neuroblastomas are eligible for this treatment (TP53 wild-type).

3:30 – 4:30 pm

Beyond Pain Crises: Acute Complications of Sickle Cell Disease (202)

1CH  Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. Although most children with SCD will now survive to adulthood, many will experience serious complications. Did you know that acute chest syndrome is the most common cause of death in SCD? Or how to determine if acute anemia is secondary to splenic sequestration or aplastic crisis? Other acute complications of SCD include infection, cerebral infarct, cholelithiasis and priapism. Through the use of interactive case studies we’ll review the presenting signs and symptoms of these acute complications, appropriate diagnostic work-up and evidence-based management. You'll leave this session confidently prepared to care for patients with sickle cell disease, beyond their pain crises.
3:30 – 4:30 pm

Central Line-Associated Bloodstream Infections in Pediatric Hem/Onc/BMT Patients: An Update and Appraisal of the Evidence (203)

1CH  Efforts to reduce central line-associated bloodstream infections (CLABSIs) have resulted in decreased rates, however, these hospital-acquired conditions remain a challenge for pediatric hematology/oncology/BMT patients. Although pediatric hem/onc centers have undertaken multiple interventions to reduce CLABSIs, the evidence base to guide CLABSI reduction efforts in this population remains limited.